Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids
- Conditions
- Breast Cancer
- Registration Number
- NCT05007379
- Lead Sponsor
- Centre Oscar Lambret
- Brief Summary
Cell-based immune therapy using modified macrophages is a promising therapeutic approach in breast cancer. The objective of this cohort study is to collect tumor samples to develop patients' derived organoids to test the antitumor activity of newly developed CAR-macrophages. Other biological samples will be collected such as blood to analyze the host inflammatory status.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Male or female aged 18 years or more
- Histologically confirmed breast cancer at any stage
- Requiring surgery or tumor biopsy as standard of care
- Any or no systemic treatment
- Signed informaed consent
- Health insurance coverage
Exclusion Criteria
- Opposed to biospecimen collection
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Antitumor activity of the CAR-macrophages against organoids from HER2 negative, HER2 low and HER2 positive breast cancers 24 months Antitumor activity of the CAR-macrophages compared to non-modified macrophages 24 months
- Secondary Outcome Measures
Name Time Method Antitumor activity of the CAR-macrophages against organoids from early and advanced breast cancers patients 24 months